Amsterdam University Medical Center

CITRYLL AND LEADING RHEUMATOLOGY CENTRES RECEIVE REUMANEDERLAND GRANT TO COLLABORATE ON NET RESEARCH TO ADVANCE NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS Learnings will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013 Oss, Netherlands – 3 October 2024 – Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces a ground-breaking collaboration with leading rheumatology centres of excellence in the Netherlands funded by ReumaNederland (Dutch Arthritis Society). Citryll will work alongside Prof. Dr. Sander Tas, from Amsterdam University Medical Centre (AUMC), Dr. Joannes Reijers, from Leiden University Medical Centre (LUMC), Dr. Rogier Thurlings, from Radboud University Medical Centre (RUMC), and Prof. Dr. Mike Nurmohamed, from Reade to further the understanding of Neutrophil Extracellular Trap (NET) biology and how it correlates to disease status and treatment outcomes in rheumatoid arthritis (RA). The project, called Signs Of the Nature of NETosis in rheumatoid arthritis (SONNET), will increase knowledge of the interplay between diseases and NETosis, a unique form of neutrophil cell death characterized by the formation of NETs, enabling the development of more efficacious personalized NET-targeting therapies. SONNET will explore different subsets of samples, correlating NETs to RA disease status and associated indications (cardiovascular disease), and detecting NETs in vivo. Renato Chirivi, Ph.D., Chief Technology Officer at Citryll, commented: “Despite available therapies, 30% of RA patients still fail to achieve sustained remission. Citryll’s lead candidate, CIT-013, has a novel therapeutic approach for the potential treatment of inflammatory diseases through the inhibition of NET release and enhanced clearing of NETs in tissue. Working with leading clinical centres on the SONNET project will be crucial to increase our knowledge on how NETs drive inflammatory diseases. The overall aim is to unlock innovative treatment options for RA, allowing a better quality of life for patients.” Jan-Willem Förch, CEO at ReumaNederland (Dutch Arthritis Society), said: “We are proud to support Citryll in this groundbreaking research collaboration with this consortium of renowned clinical centres whose research makes a difference in the lives of so many patients. Many people with rheumatoid arthritis live with constant pain and limitations in their every day life and this partnership will ensure increased knowledge in the role NETosis plays in inflammatory disease, bringing us a step closer to our mission to improve the lives of people living with the condition.” -ENDS- About Citryll Citryll is pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory processes that has yet to be addressed therapeutically. Citryll is developing the first NET-targeting therapy, and potentially creating a new class of therapeutics with broad applications across immune-mediated inflammatory diseases. Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action: it enhances the clearance of existing NETs and inhibits the formation of new NETs. By addressing this key driver of inflammation, CIT-013 has the potential to offer a more comprehensive and effective treatment option for conditions such as rheumatoid arthritis and hidradenitis suppurativa, where current therapies often fall short of providing adequate disease control. Contacts CitryllSjoerd van Gorp, COOEmail: info@citryll.com Citryll Media ContactsICR ConsiliumAmber Fennell, Sukaina Virji, Lucy FeatherstoneEmail: citryll@icrinc.com

A pivotal Boston Scientific study’s results were presented at the Heart Rhythm Society’s annual meeting and published in The New England Journal of Medicine. A six-month trial showed that Boston Scientific’s pairing of modular, wireless implants for managing discordant cardiac rhythms—and correcting dangerous ones—could be a successful approach, and the devicemaker has its heart set on an FDA approval for the system in 2025. The company linked its leadless Empower pacemaker with its Emblem subcutaneous implanted defibrillator. The approach allows one device to keep the heart from beating too fast or too slow, while the other stands by to deliver a shock to interrupt potentially fatal arrhythmias. The Emblem’s design aims to avoid some of the long-term complications seen with traditional implantable cardioverter defibrillators (ICDs) that have generators wired into the heart through the veins, such as infections; its less invasive route places leads under the skin but outside the rib cage. However, that prevents the device from also addressing bradycardia and tachycardia with direct pacing support.  That’s where Empower comes in. The leadless pacemaker, currently under development, is embedded inside the heart’s chambers to painlessly help get its beat back on track. The two devices communicate with each other wirelessly to sense abnormal rhythms, trigger the appropriate therapy and monitor the result. According to the pivotal study’s results—which were presented at the Heart Rhythm Society’s annual meeting and published in The New England Journal of Medicine—communication tests showed a success rate of 98.8%, and 97.5% of the trial’s 162 evaluated patients saw no major leadless pacemaker complications during implantation or after half a year. In addition, 61.3% of arrhythmia episodes were successfully stopped by antitachycardia pacing, with no cases in the remaining 38.7% being attributed to communication failure. “It is the first system in which medical devices, which are implanted separately in the body, are in contact with each other and work together,” said study leader Reinoud Knops, M.D., Ph.D., a professor of cardiology at Amsterdam UMC. “Its development will reduce the number of complications and invasive procedures all while maintaining patient safety.” “These findings are noteworthy, as high percentages of communication success and pain-free termination of spontaneous arrhythmia episodes indicate a potential upgrade pathway for patients currently implanted with [a subcutaneous ICD] who develop a need for [anti-tachycardia] or pacing,” said Knops.  According to Boston Scientific, all Emblem devices, with more than 130,000 already implanted worldwide, could be paired in the future with a newly placed Empower pacemaker. The company estimates that about 75% of ICD patients do not require pacing support at the time of their first implant procedure, while about 2% develop the need for it annually. “Instead of subjecting all patients to the risks of more invasive approaches, such as placing leads in the heart or tunneling them under the sternum to provide therapies they might not require, these data indicate physicians may have the opportunity to tailor therapy to the patient's individual needs and health,” Boston Scientific’s global chief medical officer, Kenneth Stein, M.D., said in a statement.

Press Release Stockholm, Sweden, December 4, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will host a virtual KOL Event on December 14, 2023 at 9:00 AM ET, featuring Dr. Arjan van de Loosdrecht, Professor of Hematology at Amsterdam UMC and Principal Investigator of the ADVANCE II trial, who will discuss the current treatment landscape for patients with Acute Myeloid Leukemia (AML) and the development of Mendus’ lead product candidate vididencel as a potential AML maintenance therapy. To register, click here. The event will focus on the new survival data being presented at the American Society of Hematology (ASH) Annual Meeting, taking place December 9-12, 2023. The results will include relapse-free and overall survival data from the ongoing ADVANCE II monotherapy Phase 2 trial and immunomonitoring data. A live question and answer session will follow the formal presentations. About Dr Arjan van de LoosdrechtDr. Arjan van de Loosdrecht, Professor of Hematology at Amsterdam UMC, passed Medical School (cum laude) in 1989 at the VU University Medical Center in Amsterdam (VUmc), The Netherlands. After a 4th years scientific laboratory training in cell biology, immunology and hematology he received his PhD graduation (cum laude) in 1993 at the department of Hematology (VUmc) on the thesis; ‘Monocyte mediated cytotoxicity in acute myeloid leukemia; Mechanisms and clinical implications’. In 1995 he graduated in Immunology. From 1993-1998 he followed clinical training in Internal Medicine followed by a fellowship in hematology (Department of Internal Medicine and Hematology at the Groningen University Medical Center, Groningen, Netherlands). From 2000, he is a staff member, since 2009 an associate professor and since 2012 a full professor of hematology at the department of Hematology, Amsterdam UMC, location VUmc, Amsterdam. His particular scientific experiences and interests are on translational hematology. He is project leader/principal investigator of the preclinical and translational immunotherapy programs in myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The major research lines focus on the immunopathogenesis of MDS/AML and on the development of leukemic dendritic cell vaccines for active specific immunization in patients with minimal residual disease (MRD) in AML and MDS. Since 2016 he is coordinator of HORIZON2020, AML-VACCiN program dealing with Dendritic Cell vaccination in AML and PI of the clinical program. He is project leader/principle investigator of clinical (translational) programs dealing with the treatment of low and high risk MDS. Regarding MDS, research focuses on the implementation of flow cytometry in the diagnosis, prognostication and monitoring of MDS. As such he is participant of the HORIZON2020 MDS-Right program. He is chair of the working group MDS of the Dutch Society of Cytometry on the implementation of flowcytometry in MDS and initiated a platform within the ELN on the implementation of flowcytometry in MDS in Europe. In addition, he is chair of the Database Sharing Committee of the International Working Group for Prognosis of MDS (IWG-PM) who developed the revised-IPSS for MDS.​ For more information, please contact:Erik Manting, CEOE-mail: ir@mendus.com ABOUT MENDUS AB (PUBL)Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/ ABOUT VIDIDENCELVididencel is an off-the-shelf immunotherapy which is being developed as a cancer maintenance treatment, aimed at improving disease-free survival following first-line treatment. Vididencel is currently studied in a Phase 2 monotherapy trial in acute myeloid leukemia (AML) and a Phase 1 safety and feasibility trial in ovarian cancer. In December 2022, positive results from the ADVANCE II monotherapy Phase 2 trial in AML were presented at the American Society of Hematology (ASH) Annual Meeting. The analysis demonstrated the potential of vididencel to induce durable relapse-free survival in the majority of patients. Vididencel has received Orphan Drug Designation in Europe and the US and Fast Track Designation in the US for the treatment of AML. Mendus has secured a manufacturing alliance with NorthX Biologics for large-scale production of vididencel. Attachment 231204_Mendus KOL Event_ENG